Monday, October 16, 2017 10:15 PM ET
Insider buy at Accelerate Diagnostics (AXDX) is Significant Breaks Selling Trend of Last Quarter
There was a significant insider purchase in Accelerate Diagnostics shares today as revealed in a filing with the SEC. One insider — Jack W Schuler, 10% Owner and Director — bought 276,200 shares in the company having a net market value of approximately $5,452,188. There have been 2 insiders with buy/sell transactions in the past 90 days prior to this filing. These trades have resulted in the purchase of 213,200 company shares and the disposition of 223,215 company shares over this time period. Adding the most recent activity to this 90-day history indicates insider trades have been net purchases of 266,185 shares and have averaged 237,538 shares per transaction over this time period.
Compared to its peers over the last 90 days, insider buy/sell trading at Accelerate Diagnostics is above the 88-company peer group average. Advanced Medical Equipment & Technology peer group saw 92 buy/sell trades during this period for an average of 1.0 transactions per company. The number of shares per buy/sell trade for Accelerate Diagnostics insiders was also higher. Within the peer group there were 610,055 shares purchased and 970,245 shares sold with company insiders disposing of 3,915 shares on average.
Significant insider buying and selling activity has been determined by eliminating all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers in data obtained in composing and writing this story.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at email@example.com. Copyright 2017 UpTick Data Technologies. All rights reserved.